{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T08:24:22Z","timestamp":1787905462447,"version":"build-2784847793"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Schizophr"],"DOI":"10.1038\/s41537-025-00639-5","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:36:37Z","timestamp":1761824197000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Low awareness of clozapine-induced agranulocytosis in a mixed-method survey of 354 patients and carers"],"prefix":"10.1038","volume":"11","author":[{"given":"Ebenezer","family":"Oloyede","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Von-de-viel","family":"Nettey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olubanke","family":"Dzahini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninoslav","family":"Majkic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Montford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostina","family":"Secchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eromona","family":"Whiskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"639_CR1","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1371\/journal.pmed.0020141","volume":"2","author":"S Saha","year":"2005","unstructured":"Saha, S. et al. A systematic review of the prevalence of schizophrenia. PLoS Med. 2, e141 (2005).","journal-title":"PLoS Med."},{"key":"639_CR2","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","volume":"174","author":"OD Howes","year":"2017","unstructured":"Howes, O. D. et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am. J. Psychiatry 174, 216\u2013229 (2017).","journal-title":"Am. J. Psychiatry"},{"key":"639_CR3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/BF00442561","volume":"99","author":"JM Kane","year":"1989","unstructured":"Kane, J. M. et al. Clozapine for the treatment-resistant schizophrenic: results of a US multicenter trial. Psychopharmacology 99, 60\u201363 (1989).","journal-title":"Psychopharmacology"},{"key":"639_CR4","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1017\/S0033291719000369","volume":"50","author":"L Xiao-Hong","year":"2020","unstructured":"Xiao-Hong, L. et al. The prevalence of agranulocytosis and related death in clozapine-treated patients: a comprehensive meta-analysis of observational studies. Psychol. Med. 50, 583\u2013594 (2020).","journal-title":"Psychol. Med."},{"key":"639_CR5","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1017\/S204579602200066X","volume":"31","author":"E Oloyede","year":"2022","unstructured":"Oloyede, E. et al. Clozapine haematological monitoring for neutropenia: a global perspective. Epidemiol. Psychiatr. Sci. 31, e83 (2022).","journal-title":"Epidemiol. Psychiatr. Sci."},{"key":"639_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S2215-0366(23)00343-7","volume":"11","author":"K Northwood","year":"2024","unstructured":"Northwood, K. et al. Evaluating the epidemiology of clozapine-associated neutropenia among people on clozapine across Australia and Aotearoa New Zealand: a retrospective cohort study. Lancet Psychiatry 11, 27\u201335 (2024).","journal-title":"Lancet Psychiatry"},{"key":"639_CR7","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S2215-0366(24)00097-X","volume":"11","author":"JM Rubio","year":"2024","unstructured":"Rubio, J. M. et al. Long-term persistence of the risk of agranulocytosis with clozapine compared with other antipsychotics: a nationwide cohort and case\u2013control study in Finland. Lancet Psychiatry 11, 443\u2013450 (2024).","journal-title":"Lancet Psychiatry"},{"key":"639_CR8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.schres.2024.08.018","volume":"272","author":"AS Brandt","year":"2024","unstructured":"Brandt, A. S. et al. The timing and severity of clozapine-associated neutropenia in the US: is the risk overstated? Schizophrenia Res. 272, 104\u2013109 (2024).","journal-title":"Schizophrenia Res."},{"key":"639_CR9","first-page":"388","volume":"382","author":"E Oloyede","year":"2023","unstructured":"Oloyede, E. et al. Clinical impact of reducing the frequency of clozapine monitoring: controlled mirror-image cohort study. Brit. J. Psychiatry 382, 388 (2023).","journal-title":"Brit. J. Psychiatry"},{"key":"639_CR10","first-page":"13818","volume":"10","author":"D Taylor","year":"2025","unstructured":"Taylor, D. et al. The safety of 12-weekly monitoring of neutrophil count in long-term clozapine patients. Acta Psychiatrica Scandinavica 10, 13818 (2025).","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"639_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41537-022-00232-0","volume":"8","author":"D Taylor","year":"2022","unstructured":"Taylor, D. et al. Distinctive pattern of neutrophil count change in clozapine-associated, life-threatening agranulocytosis. Schizophrenia 8, 21 (2022).","journal-title":"Schizophrenia"},{"key":"639_CR12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1001\/jamapsychiatry.2023.0376","volume":"80","author":"E Oloyede","year":"2023","unstructured":"Oloyede, E., Taylor, D. & MacCabe, J. J. International variation in clozapine hematologic monitoring\u2014a call for action. JAMA Psychiatry 80, 535\u2013536 (2023).","journal-title":"JAMA Psychiatry"},{"key":"639_CR13","first-page":"74","volume":"268","author":"PFJ Schulte","year":"2023","unstructured":"Schulte, P. F. J. et al. Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring: can the regulations be relaxed?. Schizophr Res. 268, 74\u201381 (2023).","journal-title":"Schizophr Res."},{"key":"639_CR14","unstructured":"Mylan. Clozaril 25\u2009mg tablets (2020, accessed 14th January 2023)."},{"key":"639_CR15","doi-asserted-by":"crossref","unstructured":"Eysenbach, G. Improving the quality of web surveys: the checklist for reporting results of internet E-Surveys CHERRIES. J. Med. Internet Res. 6, e34 (2004).","DOI":"10.2196\/jmir.6.3.e34"},{"key":"639_CR16","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S2215-0366(22)00188-2","volume":"9","author":"E Oloyede","year":"2022","unstructured":"Oloyede, E. et al. Relaxation of the criteria for entry to the UK Clozapine Central Non-Rechallenge Database: a modelling study. Lancet Psychiatry 9, 636\u2013644 (2022).","journal-title":"Lancet Psychiatry"},{"key":"639_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-021-03514-6","volume":"21","author":"E Oloyede","year":"2021","unstructured":"Oloyede, E. et al. Benign ethnic neutropenia: an analysis of prevalence, timing and identification accuracy in two large inner-city NHS hospitals. BMC Psychiatry 21, 502 (2021).","journal-title":"BMC Psychiatry"},{"key":"639_CR18","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1071\/PY18055","volume":"24","author":"K Murphy","year":"2018","unstructured":"Murphy, K. et al. Clozapine and shared care: the consumer experience. Aust. J. Prim. Health 24, 455\u2013462 (2018).","journal-title":"Aust. J. Prim. Health"},{"key":"639_CR19","doi-asserted-by":"publisher","first-page":"sgac042","DOI":"10.1093\/schizbullopen\/sgac042","volume":"3","author":"S Parkes","year":"2022","unstructured":"Parkes, S. et al. Patient\u2019s experiences of clozapine for treatment-resistant schizophrenia: a systematic review. Schizophrenia Bulletin Open 3, sgac042 (2022).","journal-title":"Schizophrenia Bulletin Open"},{"key":"639_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-023-04902-w","volume":"23","author":"E Oloyede","year":"2023","unstructured":"Oloyede, E. et al. The lived experience of clozapine discontinuation in patients and carers following suspected clozapine-induced neutropenia. BMC Psychiatry 23, 413 (2023).","journal-title":"BMC Psychiatry"},{"key":"639_CR21","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.ejon.2011.08.004","volume":"16","author":"K Leonard","year":"2012","unstructured":"Leonard, K. A European survey relating to cancer therapy and neutropenic infections: Nurse and patient viewpoints. Eur. J. Oncol. Nurs. 16, 380\u2013386 (2012).","journal-title":"Eur. J. Oncol. Nurs."},{"key":"639_CR22","first-page":"4509","volume":"28","author":"Y Takamatsu","year":"2020","unstructured":"Takamatsu, Y., Yoshida, I. & Yoshida, M. An internet-based survey exploring the awareness of febrile neutropenia in patients with malignant lymphoma. Support. Care Cancer 28, 4509\u20134516 (2020).","journal-title":"Support. Care Cancer"},{"key":"639_CR23","doi-asserted-by":"publisher","first-page":"e0145455","DOI":"10.1371\/journal.pone.0145455","volume":"10","author":"S Mantwill","year":"2015","unstructured":"Mantwill, S., Monestel-Uma\u00f1a, S. & Schulz, P. J. The relationship between health literacy and health disparities: a systematic review. PloS one 10, e0145455 (2015).","journal-title":"PloS one"},{"key":"639_CR24","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1177\/02698811211058973","volume":"36","author":"S Mace","year":"2022","unstructured":"Mace, S. et al. Incident infection during the first year of treatment - A comparison of clozapine and paliperidone palmitate long-acting injection. J. Psychopharmacol. 36, 232\u2013237 (2022).","journal-title":"J. Psychopharmacol."},{"key":"639_CR25","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1192\/j.eurpsy.2024.1816","volume":"68","author":"H Verdoux","year":"2025","unstructured":"Verdoux, H. et al. The time has come for revising the rules of clozapine blood monitoring in Europe. A joint expert statement from the European Clozapine task force. Eur. Psychiatry 68, e17 (2025).","journal-title":"Eur. Psychiatry"},{"key":"639_CR26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41537-023-00353-0","volume":"9","author":"E Oloyede","year":"2023","unstructured":"Oloyede, E. et al. What are the barriers and facilitators of clozapine use in early psychosis? A survey of UK early intervention clinicians. Schizophrenia9, 26 (2023).","journal-title":"Schizophrenia"},{"key":"639_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/20451253221141222","volume":"12","author":"E Oloyede","year":"2022","unstructured":"Oloyede, E., et al. Clozapine for treatment resistance in early psychosis: a survey of UK clinicians\u2019 training, knowledge and confidence. Therapeutic Adv. Psychopharmacol. 12, 20451253221141222 (2022).","journal-title":"Therapeutic Adv. Psychopharmacol."},{"key":"639_CR28","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.4088\/JCP.11r06977","volume":"73","author":"D Cohen","year":"2012","unstructured":"Cohen, D. et al. Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. J. Clin. psychiatry 73, 1887 (2012).","journal-title":"J. Clin. psychiatry"}],"container-title":["Schizophrenia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41537-025-00639-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41537-025-00639-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41537-025-00639-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:36:38Z","timestamp":1761824198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41537-025-00639-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["639"],"URL":"https:\/\/doi.org\/10.1038\/s41537-025-00639-5","relation":{},"ISSN":["2754-6993"],"issn-type":[{"value":"2754-6993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"129"}}